Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1510-21-0

Post Buying Request

1510-21-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1510-21-0 Usage

Description

Cholesteryl hemisuccinate is a cholesterol ester with anticancer activity. It inhibits the growth of murine C1498 myeloid and L1210 lymphocytic leukemia cells when used at concentrations of 50 and 150 μM, respectively. Cholesteryl hemisuccinate acts as an ionizable anionic detergent and is commonly used to stabilize unilamellar vesicles and liposomes. It has also been used as an emulsifying agent in various vesicular drug delivery systems for anticancer drugs, antibiotics, and oligonucleotides and to solubilize various proteins including chemokine receptor 1 as well as erythrocyte ghosts.

Uses

Cholesteryl Hemisuccinate is an oxidation product of polyunsaturated fatty acid of cholesterol that alters lysosome structure and functions and induces proinflammatory cytokine production in macrophages.

General Description

Cholesteryl hemisuccinate (CHEMS) is an acidic cholesterol ester.

Biochem/physiol Actions

CHEMS can help to maintain the stability of dioleoylphosphatidylethanolamine (DOPE). This amphipathic lipid is used in mixtures with dioleoylphosphatidylethanolamine (DOPE) to form ′pH sensitive′ fusogenic vesicles. It can control cell growth.

Check Digit Verification of cas no

The CAS Registry Mumber 1510-21-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,5,1 and 0 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1510-21:
(6*1)+(5*5)+(4*1)+(3*0)+(2*2)+(1*1)=40
40 % 10 = 0
So 1510-21-0 is a valid CAS Registry Number.
InChI:InChI=1/C31H50O4/c1-20(2)7-6-8-21(3)25-11-12-26-24-10-9-22-19-23(35-29(34)14-13-28(32)33)15-17-30(22,4)27(24)16-18-31(25,26)5/h9,20-21,23-27H,6-8,10-19H2,1-5H3,(H,32,33)

1510-21-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Sigma

  • (C6512)  Cholesterylhemisuccinate  

  • 1510-21-0

  • C6512-5G

  • 2,306.07CNY

  • Detail
  • Sigma

  • (C6512)  Cholesterylhemisuccinate  

  • 1510-21-0

  • C6512-25G

  • 7,973.55CNY

  • Detail

1510-21-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 10, 2017

Revision Date: Aug 10, 2017

1.Identification

1.1 GHS Product identifier

Product name Cholesteryl hemisuccinate

1.2 Other means of identification

Product number -
Other names CHOLESTEROL HYDROGEN SUCCINATE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1510-21-0 SDS

1510-21-0Synthetic route

succinic acid anhydride
108-30-5

succinic acid anhydride

cholesterol
57-88-5

cholesterol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
With pyridine; dmap; dimethyl sulfoxide In chloroform at 110℃; for 3h;97%
With pyridine; dmap at 20℃; for 168h;96%
Stage #1: succinic acid anhydride; cholesterol; dmap In 1,4-dioxane at 20℃; for 24h;
Stage #2: With hydrogenchloride In 1,4-dioxane; water
95%
5-cholesten-3β-yl 2-(trimethylsilyl)ethyl butanedioate
92803-49-1

5-cholesten-3β-yl 2-(trimethylsilyl)ethyl butanedioate

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
With tetrabutyl ammonium fluoride In tetrahydrofuran at 27℃; for 2h;95%
With tetrabutyl ammonium fluoride In tetrahydrofuran at 20℃;81%
cholesterol
57-88-5

cholesterol

succinoyl dichloride
543-20-4

succinoyl dichloride

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
Stage #1: cholesterol; succinoyl dichloride In acetonitrile at 50℃; for 12h;
Stage #2: With hydrogenchloride In water; acetonitrile
92%
succinic acid anhydride
108-30-5

succinic acid anhydride

cholesterol
57-88-5

cholesterol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
With toluene-4-sulfonic acid; benzene
With pyridine; toluene-4-sulfonic acid
cholesterol
57-88-5

cholesterol

succinoyl dichloride
543-20-4

succinoyl dichloride

A

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

B

cholesteryl 3-succinate
1510-20-9

cholesteryl 3-succinate

Conditions
ConditionsYield
With benzene
cholesterol
57-88-5

cholesterol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 85 percent / DCC, 4-dimethylaminopyridine / benzene / 5 h / 27 °C
2: 95 percent / tetrabutylammonium fluoride / tetrahydrofuran / 2 h / 27 °C
View Scheme
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

cholesteryloxycarbonylpropionyl chloride
87311-35-1

cholesteryloxycarbonylpropionyl chloride

Conditions
ConditionsYield
With thionyl chloride In toluene at 90℃; for 2h;100%
With oxalyl dichloride In dichloromethane at 20℃; for 12h;98%
With thionyl chloride In toluene at 80℃; for 1h;
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

2-mercaptothiazoline
96-53-7

2-mercaptothiazoline

C34H53NO3S2

C34H53NO3S2

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 1h;100%
(2-aminomethylpyridine)
3731-51-9

(2-aminomethylpyridine)

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

(3β)-cholest-5-en-3-yl 4-oxo-4-[(pyridin-2-ylmethyl)amino]butanoate

(3β)-cholest-5-en-3-yl 4-oxo-4-[(pyridin-2-ylmethyl)amino]butanoate

Conditions
ConditionsYield
With pyridine; 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide In ethyl acetate at 20℃; for 75h; Reagent/catalyst; Solvent;96%
succinic acid anhydride
108-30-5

succinic acid anhydride

cholesterol
57-88-5

cholesterol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
With pyridine; dmap; dimethyl sulfoxide In chloroform at 110℃; for 3h;97%
With pyridine; dmap at 20℃; for 168h;96%
Stage #1: succinic acid anhydride; cholesterol; dmap In 1,4-dioxane at 20℃; for 24h;
Stage #2: With hydrogenchloride In 1,4-dioxane; water
95%
5-cholesten-3β-yl 2-(trimethylsilyl)ethyl butanedioate
92803-49-1

5-cholesten-3β-yl 2-(trimethylsilyl)ethyl butanedioate

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
With tetrabutyl ammonium fluoride In tetrahydrofuran at 27℃; for 2h;95%
With tetrabutyl ammonium fluoride In tetrahydrofuran at 20℃;81%
cholesterol
57-88-5

cholesterol

succinoyl dichloride
543-20-4

succinoyl dichloride

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
Stage #1: cholesterol; succinoyl dichloride In acetonitrile at 50℃; for 12h;
Stage #2: With hydrogenchloride In water; acetonitrile
92%
succinic acid anhydride
108-30-5

succinic acid anhydride

cholesterol
57-88-5

cholesterol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
With toluene-4-sulfonic acid; benzene
With pyridine; toluene-4-sulfonic acid
cholesterol
57-88-5

cholesterol

succinoyl dichloride
543-20-4

succinoyl dichloride

A

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

B

cholesteryl 3-succinate
1510-20-9

cholesteryl 3-succinate

Conditions
ConditionsYield
With benzene
cholesterol
57-88-5

cholesterol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 85 percent / DCC, 4-dimethylaminopyridine / benzene / 5 h / 27 °C
2: 95 percent / tetrabutylammonium fluoride / tetrahydrofuran / 2 h / 27 °C
View Scheme
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

cholesteryloxycarbonylpropionyl chloride
87311-35-1

cholesteryloxycarbonylpropionyl chloride

Conditions
ConditionsYield
With thionyl chloride In toluene at 90℃; for 2h;100%
With oxalyl dichloride In dichloromethane at 20℃; for 12h;98%
With thionyl chloride In toluene at 80℃; for 1h;
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

2-mercaptothiazoline
96-53-7

2-mercaptothiazoline

C34H53NO3S2

C34H53NO3S2

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 1h;100%
(2-aminomethylpyridine)
3731-51-9

(2-aminomethylpyridine)

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

(3β)-cholest-5-en-3-yl 4-oxo-4-[(pyridin-2-ylmethyl)amino]butanoate

(3β)-cholest-5-en-3-yl 4-oxo-4-[(pyridin-2-ylmethyl)amino]butanoate

Conditions
ConditionsYield
With pyridine; 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide In ethyl acetate at 20℃; for 75h; Reagent/catalyst; Solvent;96%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

1-stearoyl-sn-glycero-3-phosphocholine
17364-19-1

1-stearoyl-sn-glycero-3-phosphocholine

1-stearoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine

1-stearoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In chloroform at 20℃; for 24h;90%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

5α,6β-dihydroxycholestan-3β-yl-hemisuccinate
10157-97-8

5α,6β-dihydroxycholestan-3β-yl-hemisuccinate

Conditions
ConditionsYield
Stage #1: cholesteryl hemisuccinate With monoperoxyphthalic acid magnesium salt hexahydrate In acetone at 57℃; for 0.5h;
Stage #2: With bismuth(lll) trifluoromethanesulfonate In acetone at 20℃; for 0.5h;
90%
1-hydroxy-pyrrolidine-2,5-dione
6066-82-6

1-hydroxy-pyrrolidine-2,5-dione

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

cholesterol-NHS ester
88848-79-7

cholesterol-NHS ester

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In tetrahydrofuran at -10 - 20℃; for 4h;89%
With dicyclohexyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 1.5h;
C17H20ClNO4S

C17H20ClNO4S

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Ethyl-diisopropylphosphoramidochloridit
104495-49-0

Ethyl-diisopropylphosphoramidochloridit

ethylene glycol
107-21-1

ethylene glycol

C52H77ClNO11PS

C52H77ClNO11PS

Conditions
ConditionsYield
at 20℃; for 10h;85.7%
monomethoxypolyethylene glycol-polylactide

monomethoxypolyethylene glycol-polylactide

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

mPEG-PLA-cholesterol

mPEG-PLA-cholesterol

Conditions
ConditionsYield
dmap; dicyclohexyl-carbodiimide In acetonitrile at 20℃; for 24h; Product distribution / selectivity;85%
8-dioxane-3-cobalt-bis(1,2-dicarbollide)
188478-29-7

8-dioxane-3-cobalt-bis(1,2-dicarbollide)

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

potassium carbonate
584-08-7

potassium carbonate

C39H78B18CoO6(1-)*K(1+)

C39H78B18CoO6(1-)*K(1+)

Conditions
ConditionsYield
In 1,2-dimethoxyethane for 6h; Reflux;83%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

1,1'-carbonyldiimidazole
530-62-1

1,1'-carbonyldiimidazole

C34H52N2O3

C34H52N2O3

Conditions
ConditionsYield
In chloroform at 38℃; for 8h;81%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

3,6,9,12,15,18-hexaoxa-1-octadecyl amine
39160-70-8

3,6,9,12,15,18-hexaoxa-1-octadecyl amine

N-{2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl}-succinamic acid 17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester
878049-46-8

N-{2-[2-(2-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethyl}-succinamic acid 17-(1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In dichloromethane at 0 - 20℃; for 20h;80%
3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-propanol
926890-48-4

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-propanol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

A

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-[succinyloxy(4-cholesteryloxy)]propane
926890-49-5

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-[succinyloxy(4-cholesteryloxy)]propane

B

1,3-Dicyclohexylurea
2387-23-7

1,3-Dicyclohexylurea

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In N,N-dimethyl-formamide at 0 - 20℃; for 6.08333h; Product distribution / selectivity;A 79%
B n/a
3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-propanol
926890-48-4

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-propanol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-[succinyloxy(4-cholesteryloxy)]propane
926890-49-5

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-[succinyloxy(4-cholesteryloxy)]propane

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In dichloromethane at 0 - 20℃; for 6h; Product distribution / selectivity;79%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

5'-O-dimethoxytrityl-2'-amino-2'-deoxyuridine
174221-86-4

5'-O-dimethoxytrityl-2'-amino-2'-deoxyuridine

C61H79N3O10

C61H79N3O10

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 24h;79%
3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-propanol

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-propanol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-[succinyloxy(4-cholesteryloxy)]propane
926890-49-5

3-[N,N-bis(2-tert-butyldiphenylsilyloxyethyl)amino]-2-(tetradecanoyloxy)-1-[succinyloxy(4-cholesteryloxy)]propane

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In N,N-dimethyl-formamide at 20℃; for 6h; Cooling with ice;79%
(Bu4N)3{(MnMo6O18)3[(OCH2)3CNH2]2}

(Bu4N)3{(MnMo6O18)3[(OCH2)3CNH2]2}

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

C8H16MnMo6N2O24(3-)*C16H36N(1+)*C31H50O4

C8H16MnMo6N2O24(3-)*C16H36N(1+)*C31H50O4

Conditions
ConditionsYield
Stage #1: cholesteryl hemisuccinate With N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline In acetonitrile at 81℃; for 0.583333h;
Stage #2: (Bu4N)3{(MnMo6O18)3[(OCH2)3CNH2]2} In acetonitrile for 24h; Reflux;
79%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

6A,6D-diamino-6A,6D-dideoxy-2A,D,3A,D-di-O-methylhexakis-(2A-G,3B-G,6B,C,E,F,G-tri-O-methyl)cyclomaltoheptaose
405906-58-3

6A,6D-diamino-6A,6D-dideoxy-2A,D,3A,D-di-O-methylhexakis-(2A-G,3B-G,6B,C,E,F,G-tri-O-methyl)cyclomaltoheptaose

6(I),6(IV)-(β-cholesteryl)-succinylamido-6(I),6(IV)-6-deoxy-per(2,3,6-O-methyl)cycloheptaose

6(I),6(IV)-(β-cholesteryl)-succinylamido-6(I),6(IV)-6-deoxy-per(2,3,6-O-methyl)cycloheptaose

Conditions
ConditionsYield
With benzotriazol-1-ol; dicyclohexyl-carbodiimide In N,N-dimethyl-formamide at 20℃; for 3h;78%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

7-ethyl-10-hydroxycamptothecin
86639-52-3, 110714-48-2, 130144-34-2

7-ethyl-10-hydroxycamptothecin

cholesterol succinate-10-(7-ethyl-10-hydroxycamptothecin)

cholesterol succinate-10-(7-ethyl-10-hydroxycamptothecin)

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 18h;78%
With pyridine; dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 25℃;71.8%
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; 4-(dimethylamino)pyridinium tosylate In dichloromethane at 20℃; for 2.5h;70%
N-hydroxyphthalimide
524-38-9

N-hydroxyphthalimide

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl (1,3-dioxoisoindolin-2-yl) succinate

(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl (1,3-dioxoisoindolin-2-yl) succinate

Conditions
ConditionsYield
With dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 16h; Inert atmosphere;75%
2-methyl-2-propenoic acid 2-hydroxyethyl ester
868-77-9

2-methyl-2-propenoic acid 2-hydroxyethyl ester

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

2-(3-((cholesteryl)oxycarbonyl)propionyloxy)ethyl methacrylate
107674-10-2

2-(3-((cholesteryl)oxycarbonyl)propionyloxy)ethyl methacrylate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; Cooling with ice;74%
5-fluorouracil
51-21-8

5-fluorouracil

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

cholesteryl 4-(2,4-dioxo-5-fluoro-(1H,3H)-pyrimidin-1-yl)-4-oxobutanoate

cholesteryl 4-(2,4-dioxo-5-fluoro-(1H,3H)-pyrimidin-1-yl)-4-oxobutanoate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In tetrahydrofuran; N,N-dimethyl-formamide at 50℃; for 48h;72%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

3-(cholesteryloxycarbonyl)propanoyl MMC
118022-81-4

3-(cholesteryloxycarbonyl)propanoyl MMC

Conditions
ConditionsYield
With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine In tetrahydrofuran; chloroform for 48h; Ambient temperature;71%
2-( N-ethylanilino)ethanol
92-50-2

2-( N-ethylanilino)ethanol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

2-(N-ethyl-N-phenylamino)ethyl 3'-((cholesteryl)oxycarbonyl)propionate

2-(N-ethyl-N-phenylamino)ethyl 3'-((cholesteryl)oxycarbonyl)propionate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 24h;70%
radicicol

radicicol

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

C49H65ClO9

C49H65ClO9

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 48h;70%
4-{[(2-hydroxyethyl)(2-naphthylmethyl)amino]methyl}-N-(tetrahydro-2H-pyran-2-yloxy)benzamide
1198587-13-1

4-{[(2-hydroxyethyl)(2-naphthylmethyl)amino]methyl}-N-(tetrahydro-2H-pyran-2-yloxy)benzamide

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

1-cholest-5-en-3-yl 4-{2-[(2-naphthylmethyl)(4-{[(tetrahydro-2H-pyran-2-yloxy)amino]carbonyl}benzyl)amino]ethyl} succinate
1198587-15-3

1-cholest-5-en-3-yl 4-{2-[(2-naphthylmethyl)(4-{[(tetrahydro-2H-pyran-2-yloxy)amino]carbonyl}benzyl)amino]ethyl} succinate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 4h;65.8%
4,6-diphenylthieno-[3,4-d]-1,3-dioxol-2-one-5,5-dioxide
54714-11-3

4,6-diphenylthieno-[3,4-d]-1,3-dioxol-2-one-5,5-dioxide

cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

Succinic acid (3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 1,1,4-trioxo-2,5-diphenyl-4,5-dihydro-1H-1λ6-thiophen-3-yl ester
127619-26-5

Succinic acid (3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 1,1,4-trioxo-2,5-diphenyl-4,5-dihydro-1H-1λ6-thiophen-3-yl ester

Conditions
ConditionsYield
With pyridine In dichloromethane at 20℃; for 24h;64%
cholesteryl hemisuccinate
1510-21-0

cholesteryl hemisuccinate

ethylene glycol
107-21-1

ethylene glycol

Succinic acid (3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 2-hydroxy-ethyl ester
204652-39-1

Succinic acid (3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 2-hydroxy-ethyl ester

Conditions
ConditionsYield
Stage #1: cholesteryl hemisuccinate With thionyl chloride In toluene at 65℃;
Stage #2: ethylene glycol With triethylamine In dichloromethane at 20℃;
63%
Stage #1: cholesteryl hemisuccinate With thionyl chloride In toluene
Stage #2: ethylene glycol With triethylamine In dichloromethane at 20℃;

1510-21-0Relevant articles and documents

Cholesterol-linked β-cyclodextrin - A thermotropic liquid-crystalline derivative

Shaikh, Vasi Ahmed Ebrahim,Lonikar, Shrikant Vitthal,Dhobale, Deepa Arun,Pawar

, p. 1975 - 1980 (2007)

Liquid-crystalline derivative of β-cyclodextrin (BCD) was prepared by covalent linking of monocholesteryl succinate (ChMS) with β-cyclodextrin. To the best of our knowledge, this was first ever attempt so far of its kind, in which BCD has been converted into its liquid-crystalline derivative through covalent linkage of a mesogen. The degree of substitution (DS) obtained was ≈2.00. The product was characterized by various techniques, such as FT-IR, NMR, DSC, hot-stage-coupled optical polarizing microscopy (OPM), microanalysis and chemical methods. Cholesterol-linked β-cyclodextrin (CDCh) derivative was found to exhibit thermotropic liquid-crystalline behavior. The product exhibited birefringence during first heating above 130°C, and it became isotropic at about 180°C, whereas the parent compound BCD decomposed without melting above 250 °C. A comparison of CDCh derivative to similar liquid-crystalline poly-saccharide derivatives is presented.

Poly(N-propargylamide)s bearing cholesteryl moieties: Preparation and optical activity

Zhang, Chaohong,Liu, Dong,Zhou, Bolin,Deng, Jianping,Yang, Wantai

, p. 832 - 838 (2012)

We synthesized a novel chiral cholesteryl-based N-propargylamide (M ch, HCCCH2NHCOCH2CH2COOch, ch = cholesteryl) from which homopolymers [P(Mch)] with different molecular weights (number-average molecular weight: 8600, 14100 and 30000) were prepared. The polymers formed helical structures with a preferential helicity. The three polymers increased in both helix content and specific rotation as the molecular weight increased. P(Mch)-8600 was studied in detail as the model polymer. P(Mch)-8600 adopted helical conformations in toluene, THF, CHCl3 and CH2Cl2, exhibited thermal stability with a decomposition temperature of 273°C and formed a lyotropic liquid crystal under the studied conditions. Copolymers of different compositions of Mch and an achiral monomer (Met) were prepared. The copolymers formed helices to different degrees depending on the specific composition, indicating an effective approach for controlling the formation of helices in synthetic helical polymers.

Matrix-molecule induced chiral enhancement effect of binary supramolecular liquid crystals

Ma, Xiao-Jing,Shen, Yong-Tao,Deng, Ke,Tang, Hong,Lei, Sheng-Bin,Wang, Chen,Yang, Yan-Lian,Feng, Xi-Zeng

, p. 4699 - 4704 (2007)

Chiral enhancement effects associated with supramolecular liquid crystalline structures are studied, using a complex of achiral molecules (4,4′-bipyridine, 4Bpy) and chiral cholesteric liquid crystalline molecules (3-cholesteryloxycarbonylpropanoic acid, C4) as the model system. Non-mesogenic achiral molecule 4Bpy is used as the matrix element. The chiral enhancement of the supramolecular liquid crystalline structures can be revealed by circular dichroism (CD) and helical twisting power measurements. It is interesting that CD spectra of the complex exhibited an appreciably enhanced chiral property in comparison with that of the pure chiral cholesteric C4 molecules at room temperature. The helical pitch measurements by the Grandjean-Cano method also confirm the chiral enhancement effect. In addition, polarizing optical microscopy (POM) measurements indicate that the addition of matrix molecules leads to the explicit expression of the chiral liquid crystalline texture, i.e. twisted grain boundary (TGBA*) phase, at the liquid crystal temperature. Differential scanning calorimetry (DSC) and variable-temperature X-ray diffraction measurements further confirm the existence of the TGBA* phase. The binary supramolecular assembly structures are investigated by scanning tunneling microscope (STM) and the formation of hydrogen bonds between the chiral mesogens and the achiral matrix molecules can be directly observed. The variable-temperature Fourier transform infrared (FTIR) results further demonstrate that the hydrogen bonds persist until 168 °C. These results indicate that the introduction of a bifunctional aromatic base such as bipyridine could lead to self-assembled supramolecular architectures with discernible enhancements of chiral properties. The Royal Society of Chemistry.

Synthesis of novel thiol-reactive amphiphilic lipids based on cholesterol for protein-liposome coupling

Kley, Joerg T.,Fichert, Thomas,Massing, Ulrich

, p. 319 - 327 (1998)

The synthesis of a series of coupling lipids designed for covalently linking proteins to liposomes is described. The new compounds have in common a cholesterylsuccinyl unit as a lipid anchor and a thiol-reactive maleimidobenzoyl unit which are linked by alkyl or (poly)ethylene glycol spacers that differ in length and polarity.

Synthesis of α-carboranyl-α-acyloxy-amides as potential BNCT agents

Jonnalagadda, Subash C.,Cruz, Jonathan S.,Connell, Ryan J.,Scott, Patricia M.,Mereddy, Venkatram R.

, p. 4314 - 4317 (2009)

Novel α-carboranyl-α-acyloxy-amides were prepared as potential BNCT agents utilizing three-component Passerini reaction. Preliminary cytotoxicity of the representative compounds on two brain tumor cell lines (U-87 and A-172) showed no effect on cell viability; an essential requirement for utility as potential BNCT agents.

Electrical conformational bistability of dimesogen molecules with a molecular chord structure

Yang, Yan-Lian,Chan, Qi-Lin,Ma, Xiao-Jing,Deng, Ke,Shen, Yong-Tao,Feng, Xi-Zeng,Wang, Chen

, p. 6889 - 6893 (2006)

Touching a chord: A field-dependent conformational change occurs in dimesogen molecules with flexible linking chains, which illustrates a molecular chord structure that is switchable by an electric field (see picture; HOPG = highly oriented pyrolytic graphite). No discernible changes are observed for dimesogen molecules with rigid linkers. (Figure Presented).

Physico-chemical interactions of a new rod-coil-rod polymer with liposomal system: Approaches to applications in tryptophan-related therapies

Cardoso dos Santos, Marinalva,Silva de Farias, Bruna,da Costa Cabrera, Diego,Roberto Sant'Anna Cadaval Junior, Tito,Antonio de Almeida Pinto, Luiz,Gon?alves Dal-Bó, Alexandre,de Lima, Vania Rodrigues

, (2021)

This work describes the synthesis of the new supramolecular rod-coil-rod polymer, designated as cholesterol-PEO1000-tryptophan (Chl-PEO-Trp), as well as its effects on the physico-chemical properties of phosphatidylcholine (PC)-based liposomes. The molecular interactions between the Chl-PEO-Trp and PC were characterized by HATR-FTIR, DSC, NMR, DLS and zeta (ζ) potential techniques. The Chl-PEO-Trp polymer yield was 75 %. FTIR and DSC data showed that the motion of almost all PC groups was restricted by the polymer, and it promoted a decrease of the trans-gauche isomerization of the PC methylene, restricting the mobility of the hydrophobic region of the liposomes. NMR analyses indicated a Chl-PEO-Trp-induced restriction in the rotation of the PC phosphorus and a discreet increase of the hydrogen mobility of the choline. Despite this increase in the rotation of the choline, DLS and ζ-potential analyses suggested a reorientation of the choline group toward the system surface, which contributed, along with the other physico-chemical effects, to a globally packed membrane arrangement and reduced liposome size. Data described in this work were correlated to possible applications of the Chl-PEO-Trp in its free or PC liposome-loaded forms in the diagnosis and therapy of cancer, SARS caused by coronaviruses, and central nervous system-related diseases.

Cathepsin B-sensitive cholesteryl hemisuccinate-gemcitabine prodrug nanoparticles: Enhanced cellular uptake and intracellular drug controlled release

Xu, Yanyun,Geng, Jianqi,An, Ping,Xu, Yan,Huang, Jin,Lu, Wei,Liu, Shiyuan,Yu, Jiahui

, p. 6985 - 6992 (2015)

Gemcitabine [2′,2′-difluoro-2′-deoxycytidine (dFdC)], firstline treatment for pancreatic cancer in the clinic, is a cytotoxic nucleoside analogue. Nucleoside transporters are required in the transport of gemcitabine into cells since it is a hydrophilic compound. Actually, there are significant drawbacks for the application of gemcitabine in clinic, including a short half-life and serious side effects. In order to overcome the mentioned drawbacks, a novel prodrug, cholesteryl hemisuccinate-gemcitabine (CHSdFdC), was synthesized through covalently coupling the amino group of gemcitabine with the carboxylic group of cholesteryl hemisuccinate. The amphiphilic prodrug self-assembled spontaneously as nanoparticles in aqueous media confirmed by transmission electron microscopy (TEM). Dynamic light scattering (DLS) measurement revealed that the mean particle size is approximately 200 nm in aqueous media. The CHSdFdC nanoparticles displayed accumulative controlled drug release in simulated lysosome conditions (pH 5.0 NaAc buffer solution containing cathepsin B); the amount of drug release reached up to 80% within 10 h. However, there was almost no drug release in pH 7.4 PBS and pH 5.0 NaAc buffer solutions without cathepsin B. All these results indicated the intracellularly controlled drug release manner of the CHSdFdC nanoparticles. The controlled release of dFdC from the CHSdFdC nanoparticles was related closely to cleavage of amide bonds by cathepsin B. The CHSdFdC nanoparticles exhibited increased ability to inhibit cell growth compared with gemcitabine in vitro. Meanwhile, the CHSdFdC nanoparticles exhibited enhanced cellular uptake ability against Bxpc-3 cells, and the amount of CHSdFdC was about 15 fold of gemcitabine during the 2.5 h incubation. All these results showed that the CHSdFdC nanoparticle prodrug has great potential in the treatment of pancreatic cancer.

Chol-Dex nanomicelles: Synthesis, characterization and evaluation as efficient drug carriers for colon targeting

Goyal, Preeti,singh, Mahak,Kumar, Pradeep,Gupta, Alka

, (2021)

Core-shell structures obtained from amphiphilic molecules on self-assembly in a medium have emerged as an important tool in the area of biomedical sciences. Here, we have synthesized cholesteryl-dextran (Chol-Dex) amphiphiles in sufficiently high yields via conjugation of cholesteryl hemisuccinate to dextran in two different concentrations (5 and 10%). After physicochemical and spectral analysis, the nanomicelles were subjected to size measurements. DLS and TEM confirmed the formation of core-shell type of nanomicelles. Hydrophobic drug-entrapped formulations (Metronidazole and Rifampicin) displayed sustained release behaviour of drugs from them. Sustained release at neutral pH demonstrated usefulness of the non-toxic delivery system for colon specific diseases.

LHRHa aided liposomes targeting to human ovarian tumor cells: Preparation and cellular uptake

Yuan, Wen-Min,Song, Qin-Guo,Zhang, Zhi-Rong,Fu, Yao,Liu, Ji,He, Qin

, p. 434 - 438 (2008)

In this study, a synthetic nonapeptide similar to luteinizing hormone-releasing hormone (LHRHa), the ligand of an extracellular membrane receptor specific to ovarian tumor cells, was selected as targeting moiety and electrically adsorbed to the negatively charged liposomes composed of phos-pholipid and monocholesterolsuccinate. Docetaxel, as the first line chemotherapy for ovarian tumor, was chosen to be encapsulated into the liposomes. And a high encapsulate efficiency (93%) and drug loading efficiency (20%) of liposomes were achieved via central composite design. In order to investigate the targeting efficiency of the drug delivery system, in vitro cell uptake was determined and the results showed an increasing uptake of LHRHa aided liposomes compared to normal ones.

Preparation and application of brain glioma targeting berberine and folic acid modified lipid material

-

Paragraph 0009; 0018, (2021/09/21)

The invention discloses preparation and application of a brain glioma targeting berberine and folic acid modified lipid material, and can be used for preparing lipidosome modified by brain glioma targeting Tween 80 coated berberine and folic acid. The liposome surface is coated with Tween 80 and can pass through the blood-brain barrier effectively through receptor-mediated endocytosis after binding with low density lipoprotein receptors to deliver the drug to the brain. In addition, the liposome uses folic acid and berberine to modify brain glioma targeting and mitochondrial targeting capacity of the liposome, and the long chain of polyethylene glycol is introduced to stabilize the liposome. A new thought and a method can be provided for targeted therapy of glioma, and a wide application prospect is provided. pH MDR. The utility model can provide a new idea and a method for targeted therapy of brain glioma.

Folic acid modified liposome complex and its preparation and use (by machine translation)

-

Paragraph 0049; 0055; 0056, (2019/06/30)

The present invention relates to folic acid modified liposome complex and its preparation and use, which belongs to the field of medicine. The present invention provides folic acid modified liposome complex, it is composed of the following weight proportion of the raw materials with the: loaded with the BIM - S gene recombinant expression vector 1 parts, folic acid modified liposome 5 more than, wherein said folic acid is modified liposome comprising (2, 3 - dioleoyl - propyl) - trimethylamine, cholesterol, polyethylene glycol - succinimide - cholesterol and folic acid - polyethylene glycol - succinimide - cholesterol prepared of raw materials. The invention also provides the liposome method for preparing the compound and use thereof. The present invention provides of the folic acid modified liposome composition not only can kill the lung cancer cell, can also be through targeting TAM to influence the tumor micro-environment, for clinical treatment of lung cancer provides a new choice of drug use for. (by machine translation)

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1510-21-0